We also discuss long-term implications for T2DM care, weight management and, ultimately, cardiorenal disease prevention in patients with T2DM and/or overweight or obesity
Raufman JP, Singh L, Singh G et al
The questions that matter more, and the ones I get less often, are the ones this article is built to answer: how do these medications actually differ, who should choose which one, what should you expect from treatment, and how do you tell a careful clinical program apart from a prescription mill
As a GLP-1 receptor agonist analog, it has been examined in preclinical and published research models studying GLP-1 receptor binding dynamics, cAMP-mediated signaling cascades, and comparative incretin pathway biology
CrossRef Metabolic DysfunctionAssociated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences .2026;[Epub] CrossRef The MASLD Journey in the General Population: LinkagetoCare and PatientReported Uptake of Fibrosis Risk Assessment Joo Hyun Oh, JunHyuk Lee, Sang Bong Ahn, Eunjoo Kwon, Eileen L
2024 Jul 12;62(3):1618
